Print Page   |   Contact Us   |   Sign In   |   Join
News and Press: Industry News

FDA Roadmap Highlights Opioids, Gene Therapy, Biosimilars

Friday, January 12, 2018   (0 Comments)
Share |



Dive Brief:

  • The Food and Drug Administration's 2018 strategic policy roadmap highlights the battle against opioid addiction, the growth of cell and gene therapy, and using competition to improve access and make drugs more affordable.
  • Identifying where pharma is "inappropriately impeding generic competition" is also on the agenda, including guidance on REMS. 
  • Final guidance on communication from developers to payers about economic consequences of products is expected, in a bid to promote value-based contracting.

Read the full article here.

Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership  ::  Legal